Editor, Ophthalmology Times
Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment on macular degeneration-treated mice in space.
Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.
Results showed LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, while LNZ101 showed similar results but ultimately failed to show superiority to LNZ100.
Rahul S Tonk, MD, MBA, sat down to discuss a roundtable discussion he had on DMEK and DSEK surgery at this year's ASCRS meeting held in Boston, Massachusetts, from Friday, April 5, to Monday, April 8, 2024.
Alejandro Espaillat, MD, sat down to discuss his presentation on pearls for the anterior segment surgeon at this year's ASCRS meeting held in Boston, Massachusetts.
Neda Nikpoor, MD, sat down to discuss her presentation on the single-site study on the effectiveness of a sterile model with two ALLYs, in two operating rooms against a model with only one laser for two rooms at this year's ASCRS meeting held in Boston, Massachusetts.
Ula Jurkunas, MD, sat down to discuss her presentation on the management of anterior corneal disease at this year's ASCRS meeting held in Boston, Massachusetts.
Roger Kennedy, director of marketing at BioTissue sat down to discuss the new products the company will be unveiling at this year's ASCRS meeting held in Boston, Massachusetts.
Jennifer Loh, MD, sat down to discuss her presentation on major eye issues that can interfere with refractive cataract surgery, specifically dry eye disease, at this year's ASCRS meeting held in Boston, Massachusetts.
The 2 organizations to receive initial gifts will be Sight for Life and Eye Corps.
The Osprey trial has started dosing while the Apteryx trial is anticipated to begin within the next few weeks.
Following the CRL from the FDA last year, Aldeyra is planning to initiate a dry eye chamber clinical trial in the first half of 2024.
Stargardt disease is the most common inherited retinal dystrophy (causing blurring or loss of central vision) in both adults and children.
The new cohort will add patients living with IRDs caused by mutations in multiple genes to the already existing cohort of patients with IRDs caused by single gene mutations.
Results from the trial by Nannodropper show microdrops could reduce waste, cost, and side effects while being as effective as traditional size drops.
The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.
Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R).
Study findings show every $1 invested in eye care sees $36 in return globally
The trial evaluated nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy.
The reverse stock split is “part of the Company’s plan to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market."
Alexander Movshovich, MD, PhD, a specialist in keratopigmentation, sat down to talk about the controversy surrounding the procedure after it went viral on social media.
The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play central role in tear film homeostasis
The Clareon platform will be available in India in 2 Presbyopia correcting IOL technologies: the Clareon PanOptix and Clareon Vivity.
The organization aims to educate viewers of dangers and safety precautions ahead of the eclipses.
LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens created by the company’s proprietary 3D printing technology.
Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
John Bertrand, CEO of Digital Diagnostics sits down with Managing Editor David Hutton of Ophthalmology Times to talk about the importance of early screening for diabetic retinopathy as well as other diagnostic options for National Save Your Vision month.
TL-925 is a first in class, topical Bruton’s tyrosine kinase (BTK) inhibitor that prevents mast cell activation and degranulation, and also blocks the cytokine-driven inflammatory response, and restores lacrimal unit homeostasis, offering the potential for disease modification
David Sola-Del Valle, MD, sat down with David Hutton of Ophthalmology Times to discuss his talk at the annual American Glaucoma Society meeting held in Huntington Beach, about the importance of bridging the language barrier in patients who may not be fluent in English.
April Maa, MD, sat down with David Hutton of Ophthalmology Times to discuss her presentation at the annual American Glaucoma Society meeting held in Huntington Beach, about tips and tricks for implementing telehealth into ophthalmology.
